Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2016, Article ID 6978936, 9 pages
http://dx.doi.org/10.1155/2016/6978936
Review Article

The Role of Toll-Like Receptor 4 in Infectious and Noninfectious Inflammation

Dipartimento di Biotecnologie e Scienze della Vita, Università degli Studi dell’Insubria, Via J. H. Dunant 3, 21100 Varese, Italy

Received 16 March 2016; Accepted 4 May 2016

Academic Editor: Marisa I. Gómez

Copyright © 2016 Monica Molteni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Akira and K. Takeda, “Toll-like receptor signaling,” Nature Reviews Immunology, vol. 4, no. 7, pp. 1–16, 2004. View at Google Scholar
  2. L. Yu, L. Wang, and S. Chen, “Endogenous toll-like receptor ligands and their biological significance,” Journal of Cellular and Molecular Medicine, vol. 14, no. 11, pp. 2592–2603, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. K. R. Taylor, J. M. Trowbridge, J. A. Rudisill, C. C. Termeer, J. C. Simon, and R. L. Gallo, “Hyaluronan fragments stimulate endothelial recognition of injury through TLR4,” The Journal of Biological Chemistry, vol. 279, no. 17, pp. 17079–17084, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Frantz, L. Kobzik, Y.-D. Kim et al., “Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium,” The Journal of Clinical Investigation, vol. 104, no. 3, pp. 271–280, 1999. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Kielian, “Toll-like receptors in CNS glial inflammation and homeostasis,” Journal of Neuroscience Research, vol. 83, no. 5, pp. 711–730, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Medzhitov, P. Preston-Hurlburt, and C. A. Janeway Jr., “A human homologue of the Drosophila toll protein signals activation of adaptive immunity,” Nature, vol. 388, no. 6640, pp. 394–397, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. Y. Nagai, S. Akashi, M. Nagafuku et al., “Essential role of MD-2 in LPS responsiveness and TLR4 distribution,” Nature Immunology, vol. 3, no. 7, pp. 667–672, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. A. B. Schromm, E. Lien, P. Henneke et al., “Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling,” The Journal of Experimental Medicine, vol. 194, no. 1, pp. 79–88, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Shimazu, S. Akashi, H. Ogata et al., “MD-2, a molecule that confers lipopolysaccharide responsiveness on toll-like receptor 4,” Journal of Experimental Medicine, vol. 189, no. 11, pp. 1777–1782, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Viriyakosol, P. S. Tobias, R. L. Kitchens, and T. N. Kirkland, “MD-2 binds to bacterial lipopolysaccharide,” The Journal of Biological Chemistry, vol. 276, no. 41, pp. 38044–38051, 2001. View at Google Scholar · View at Scopus
  11. H. M. Kim, B. S. Park, J.-I. Kim et al., “Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist eritoran,” Cell, vol. 130, no. 5, pp. 906–917, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. B. S. Park, D. H. Song, H. M. Kim, B.-S. Choi, H. Lee, and J.-O. Lee, “The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex,” Nature, vol. 458, no. 7242, pp. 1191–1195, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. U. Ohto, K. Fukase, K. Miyake, and T. Shimizu, “Structural basis of species-specific endotoxin sensing by innate immune receptor TLR4/MD-2,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 19, pp. 7421–7426, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Zanoni, R. Ostuni, L. R. Marek et al., “CD14 controls the LPS-induced endocytosis of toll-like receptor 4,” Cell, vol. 147, no. 4, pp. 868–880, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. G. M. Barton and R. Medzhitov, “Toll-like receptor signaling pathways,” Science, vol. 300, no. 5625, pp. 1524–1525, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Rajaiah, D. J. Perkins, D. D. C. Ireland, and S. N. Vogel, “CD14 dependence of TLR4 endocytosis and TRIF signaling displays ligand specificity and is dissociable in endotoxin tolerance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 27, pp. 8391–8396, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. M. A. Nahid, K. M. Pauley, M. Satoh, and E. K. L. Chan, “miR-146a is critical for endotoxin-induced tolerance: implication in innate immunity,” The Journal of Biological Chemistry, vol. 284, no. 50, pp. 34590–34599, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. L. A. O'Neill, F. J. Sheedy, and C. E. McCoy, “MicroRNAs: the fine-tuners of Toll-like receptor signalling,” Nature Reviews Immunology, vol. 11, no. 3, pp. 163–175, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Poltorak, X. He, I. Smirnova et al., “Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene,” Science, vol. 282, no. 5396, pp. 2085–2088, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. S. T. Qureshi, L. Larivière, G. Leveque et al., “Endotoxin-tolerant mice have mutations in toll-like receptor 4 (Tlr4),” Journal of Experimental Medicine, vol. 189, no. 4, pp. 615–625, 1999. View at Publisher · View at Google Scholar · View at Scopus
  21. E. A. Kurt-Jones, L. Popova, L. Kwinn et al., “Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus,” Nature Immunology, vol. 1, no. 5, pp. 398–401, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. T. H. Flo, L. Ryan, E. Latz et al., “Involvement of Toll-like receptor (TLR) 2 and TLR4 in cell activation by mannuronic acid polymers,” The Journal of Biological Chemistry, vol. 277, no. 38, pp. 35489–35495, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Yang, S. Sugawara, T. Monodane et al., “Micrococcus luteus teichuronic acids activate human and murine monocytic cells in a CD14- and toll-like receptor 4-dependent manner,” Infection and Immunity, vol. 69, no. 4, pp. 2025–2030, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Rallabhandi, J. Bell, M. S. Boukhvalova et al., “Analysis of TLR4 polymorphic variants: new insights into TLR4/MD-2/CD14 stoichiometry, structure, and signaling,” The Journal of Immunology, vol. 177, no. 1, pp. 322–332, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. K. Gomi, K. Kawasaki, Y. Kawai, M. Shiozaki, and M. Nishijima, “Toll-like receptor 4-MD-2 complex mediates the signal transduction induced by flavolipin, an amino acid-containing lipid unique to Flavobacterium meningosepticum,” The Journal of Immunology, vol. 168, no. 6, pp. 2939–2943, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Romani, “Immunity to fungal infections,” Nature Reviews Immunology, vol. 11, no. 4, pp. 275–288, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Modhiran, D. Watterson, D. A. Muller et al., “Dengue virus NS1 protein activates cells via Toll-like receptor 4 and disrupts endothelial cell monolayer integrity,” Science Translational Medicine, vol. 7, no. 304, Article ID 304ra142, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Kawasaki, S. Akashi, R. Shimazu, T. Yoshida, K. Miyake, and M. Nishijima, “Mouse toll-like receptor 4·MD-2 complex mediates lipopolysaccharide—mimetic signal transduction by Taxol,” The Journal of Biological Chemistry, vol. 275, no. 4, pp. 2251–2254, 2000. View at Publisher · View at Google Scholar · View at Scopus
  29. G. D. Kutuzova, R. M. Albrecht, C. M. Erickson, and N. Qureshi, “Diphosphoryl lipid A from Rhodobacter sphaeroides blocks the binding and internalization of lipopolysaccharide in RAW 264.7 cells,” The Journal of Immunology, vol. 167, no. 1, pp. 482–489, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Macagno, M. Molteni, A. Rinaldi et al., “A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression,” Journal of Experimental Medicine, vol. 203, no. 6, pp. 1481–1492, 2006. View at Publisher · View at Google Scholar · View at Scopus
  31. C. Termeer, F. Benedix, J. Sleeman et al., “Oligosaccharides of hyaluronan activate dendritic cells via toll-like receptor 4,” The Journal of Experimental Medicine, vol. 195, no. 1, pp. 99–111, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Schaefer, A. Babelova, E. Kiss et al., “The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages,” The Journal of Clinical Investigation, vol. 115, no. 8, pp. 2223–2233, 2005. View at Publisher · View at Google Scholar · View at Scopus
  33. S. P. Gondokaryono, H. Ushio, F. Niyonsaba et al., “The extra domain A of fibronectin stimulates murine mast cells via toll-like receptor 4,” Journal of Leukocyte Biology, vol. 82, no. 3, pp. 657–665, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. G. B. Johnson, G. J. Brunn, Y. Kodaira, and J. L. Platt, “Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by toll-like receptor 4,” Journal of Immunology, vol. 168, no. 10, pp. 5233–5239, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Midwood, S. Sacre, A. M. Piccinini et al., “Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease,” Nature Medicine, vol. 15, no. 7, pp. 774–780, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. M. T. Lotze and K. J. Tracey, “High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal,” Nature Reviews Immunology, vol. 5, no. 4, pp. 331–342, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. M. F. Roelofs, W. C. Boelens, L. A. B. Joosten et al., “Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis,” Journal of Immunology, vol. 176, no. 11, pp. 7021–7027, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Ohashi, V. Burkart, S. Flohé, and H. Kolb, “Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex,” The Journal of Immunology, vol. 164, no. 2, pp. 558–561, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Asea, M. Rehli, E. Kabingu et al., “Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4,” Journal of Biological Chemistry, vol. 277, no. 17, pp. 15028–15034, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. M. A. Chase, D. S. Wheeler, K. M. Lierl, V. S. Hughes, H. R. Wong, and K. Page, “Hsp72 induces inflammation and regulates cytokine production in airway epithelium through a TLR4- and NF-κB-dependent mechanism,” The Journal of Immunology, vol. 179, no. 9, pp. 6318–6324, 2007. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Fang, Y. Wu, X. Huang et al., “Toll-like receptor 4 (TLR4) is essential for Hsp70-like protein 1 (HSP70L1) to activate dendritic cells and induce Th1 response,” The Journal of Biological Chemistry, vol. 286, no. 35, pp. 30393–30400, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. R. M. Vabulas, S. Braedel, N. Hilf et al., “The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the toll-like receptor 2/4 pathway,” Journal of Biological Chemistry, vol. 277, no. 23, pp. 20847–20853, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. W. Wu, Q. Chen, F. Geng et al., “Calcineurin B stimulates cytokine production through a CD14-independent Toll-like receptor 4 pathway,” Immunology and Cell Biology, vol. 94, no. 3, pp. 285–292, 2015. View at Publisher · View at Google Scholar
  44. A. Biragyn, P. A. Ruffini, C. A. Leifer et al., “Toll-like receptor 4-dependent activation of dendritic cells by β-defensin 2,” Science, vol. 298, no. 5595, pp. 1025–1029, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Vogl, K. Tenbrock, S. Ludwig et al., “Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock,” Nature Medicine, vol. 13, no. 9, pp. 1042–1049, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. L. Guillot, V. Balloy, F. X. McCormack, D. T. Golenbock, M. Chignard, and M. Si-Tahar, “Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4,” The Journal of Immunology, vol. 168, no. 12, pp. 5989–5992, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Tarkowski, J. Bjersing, A. Shestakov, and M. I. Bokarewa, “Resistin competes with lipopolysaccharide for binding to toll-like receptor 4,” Journal of Cellular and Molecular Medicine, vol. 14, no. 6, pp. 1419–1431, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. S. T. Smiley, J. A. King, and W. W. Hancock, “Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4,” Journal of Immunology, vol. 167, no. 5, pp. 2887–2894, 2001. View at Publisher · View at Google Scholar · View at Scopus
  49. C. R. Stewart, L. M. Stuart, K. Wilkinson et al., “CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer,” Nature Immunology, vol. 11, no. 2, pp. 155–161, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. C. Erridge, “Endogenous ligands of TLR2 and TLR4: agonists or assistants?” Journal of Leukocyte Biology, vol. 87, no. 6, pp. 989–999, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Jiang, J. Liang, J. Fan et al., “Regulation of lung injury and repair by Toll-like receptors and hyaluronan,” Nature Medicine, vol. 11, no. 11, pp. 1173–1179, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Lehnardt, E. Schott, T. Trimbuch et al., “A vicious cycle involving release of heat shock protein 60 from injured cells and activation of toll-like receptor 4 mediates neurodegeneration in the CNS,” The Journal of Neuroscience, vol. 28, no. 10, pp. 2320–2331, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Yang, H. S. Hreggvidsdottir, K. Palmblad et al., “A critical cysteine is required for HMGB1 binding to toll-like receptor 4 and activation of macrophage cytokine release,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 26, pp. 11942–11947, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. K. Hoshino, O. Takeuchi, T. Kawai et al., “Cutting edge: toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product,” The Journal of Immunology, vol. 162, no. 7, pp. 3749–3752, 1999. View at Google Scholar
  55. A. D. O'Brien, D. L. Rosenstreich, I. Scher, G. H. Campbell, R. P. MacDermott, and S. B. Formal, “Genetic control of susceptibility to Salmonella typhimurium in mice: role of the LPS gene,” The Journal of Immunology, vol. 124, no. 1, pp. 20–24, 1980. View at Google Scholar · View at Scopus
  56. J. P. Woods, J. A. Frelinger, G. Warrack, and J. G. Cannon, “Mouse genetic locus Lps influences susceptibility to Neisseria meningitidis infection,” Infection and Immunity, vol. 56, no. 8, pp. 1950–1955, 1988. View at Google Scholar · View at Scopus
  57. T. Roger, C. Froidevaux, D. Le Roy et al., “Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 7, pp. 2348–2352, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. M. G. Netea, C. Wijmenga, and L. A. J. O'Neill, “Genetic variation in Toll-like receptors and disease susceptibility,” Nature Immunology, vol. 13, no. 6, pp. 535–542, 2012. View at Publisher · View at Google Scholar · View at Scopus
  59. B. Ferwerda, M. B. B. McCall, K. Verheijen et al., “Functional consequences of toll-like receptor 4 polymorphisms,” Molecular Medicine, vol. 14, no. 5-6, pp. 346–352, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Fukusaki, N. Ohara, Y. Hara, A. Yoshimura, and K. Yoshiura, “Evidence for association between a Toll-like receptor 4 gene polymorphism and moderate/severe periodontitis in the Japanese population,” Journal of Periodontal Research, vol. 42, no. 6, pp. 541–545, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. A. Mansur, L. von Gruben, A. F. Popov et al., “The regulatory toll-like receptor 4 genetic polymorphism rs11536889 is associated with renal, coagulation and hepatic organ failure in sepsis patients,” Journal of Translational Medicine, vol. 12, no. 1, pp. 177–185, 2014. View at Publisher · View at Google Scholar · View at Scopus
  62. K. Sato, A. Yoshimura, T. Kaneko et al., “A single nucleotide polymorphism in 3'-untranslated region contributes to the regulation of toll-like receptor 4 translation,” Journal of Biological Chemistry, vol. 287, no. 30, pp. 25163–25172, 2012. View at Publisher · View at Google Scholar · View at Scopus
  63. S. M. Opal, P. F. Laterre, B. Francois et al., “Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial,” Journal of the American Medical Association, vol. 309, no. 11, pp. 1154–1162, 2013. View at Google Scholar
  64. N. A. Hutchins, J. Unsinger, R. S. Hotchkiss, and A. Ayala, “The new normal: immunomodulatory agents against sepsis immune suppression,” Trends in Molecular Medicine, vol. 20, no. 4, pp. 224–233, 2014. View at Publisher · View at Google Scholar · View at Scopus
  65. M. Andrassy, H. C. Volz, J. C. Igwe et al., “High-mobility group box-1 in ischemia-reperfusion injury of the heart,” Circulation, vol. 117, no. 25, pp. 3216–3226, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. R. F. van Golen, T. M. van Gulik, and M. Heger, “The sterile immune response during hepatic ischemia/reperfusion,” Cytokine and Growth Factor Reviews, vol. 23, no. 3, pp. 69–84, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. D. M. Yellon and D. J. Hausenloy, “Myocardial reperfusion injury,” The New England Journal of Medicine, vol. 357, no. 11, pp. 1074–1135, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. J. Howell, P. Gow, P. Angus, and K. Visvanathan, “Role of toll-like receptors in liver transplantation,” Liver Transplantation, vol. 20, no. 3, pp. 270–280, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. J.-I. Oyama, C. Blais Jr., X. Liu et al., “Reduced myocardial ischemia-reperfusion injury in toll-like receptor 4-deficient mice,” Circulation, vol. 109, no. 6, pp. 784–789, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. D. J. Kaczorowski, A. Nakao, R. Vallabhaneni et al., “Mechanisms of Toll-like receptor 4 (TLR4)-mediated inflammation after cold ischemia/reperfusion in the heart,” Transplantation, vol. 87, no. 10, pp. 1455–1463, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. A. Tsung, R. Sahai, H. Tanaka et al., “The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion,” Journal of Experimental Medicine, vol. 201, no. 7, pp. 1135–1143, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. J. R. Caso, J. M. Pradillo, O. Hurtado, P. Lorenzo, M. A. Moro, and I. Lizasoain, “Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke,” Circulation, vol. 115, no. 12, pp. 1599–1608, 2007. View at Publisher · View at Google Scholar · View at Scopus
  73. H. Wu, G. Chen, K. R. Wyburn et al., “TLR4 activation mediates kidney ischemia/reperfusion injury,” Journal of Clinical Investigation, vol. 117, no. 10, pp. 2847–2859, 2007. View at Publisher · View at Google Scholar · View at Scopus
  74. F. Hua, J. Ma, T. Ha et al., “Activation of Toll-like receptor 4 signaling contributes to hippocampal neuronal death following global cerebral ischemia/reperfusion,” Journal of Neuroimmunology, vol. 190, no. 1-2, pp. 101–111, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. A. J. Chong, A. Shimamoto, C. R. Hampton et al., “Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart,” The Journal of Thoracic and Cardiovascular Surgery, vol. 128, no. 2, pp. 170–179, 2004. View at Publisher · View at Google Scholar · View at Scopus
  76. D. J. Kaczorowski, A. Nakao, K. P. Mollen et al., “Toll-like receptor 4 mediates the early inflammatory response after cold ischemia/reperfusion,” Transplantation, vol. 84, no. 10, pp. 1279–1287, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. A. Shimamoto, A. J. Chong, M. Yada et al., “Inhibition of toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury,” Circulation, vol. 114, no. 1, pp. I270–I274, 2006. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Soldo, M. Molteni, C. Rossetti et al., “CyP, a toll-like receptor 4 antagonist, protects the heart from ischemia/reperfusion injury,” European Heart Journal, vol. 32, supplement 1, p. 690, 2011. View at Google Scholar
  79. K. A. Mcdonald, H. Huang, S. Tohme et al., “Toll-like receptor 4 (TLR4) antagonist eritoran tetrasodium attenuates liver ischemia and reperfusion injury through inhibition of high-mobility group box protein B1 (HMGB1) signaling,” Molecular Medicine, vol. 20, pp. 639–648, 2015. View at Google Scholar
  80. M. T. Heneka, M. J. Carson, J. El. Khoury et al., “Neuroinflammation in Alzheimer's disease,” The Lancet Neurology, vol. 14, no. 4, pp. 388–405, 2015. View at Publisher · View at Google Scholar
  81. A. Vezzani, “Epilepsy and inflammation in the brain: overview and pathophysiology,” Epilepsy Currents, vol. 14, no. 1, pp. 3–7, 2014. View at Publisher · View at Google Scholar · View at Scopus
  82. T. C. Frank-Cannon, L. T. Alto, F. E. McAlpine, and M. G. Tansey, “Does neuroinflammation fan the flame in neurodegenerative diseases?” Molecular Neurodegeneration, vol. 4, no. 1, pp. 47–60, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. J. K. Olson and S. D. Miller, “Microglia initiate central nervous system innate and adaptive immune responses through multiple TLRs,” The Journal of Immunology, vol. 173, no. 6, pp. 3916–3924, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. A. J. Tarr, K. A. McLinden, D. Kranjac, R. A. Kohman, W. Amaral, and G. W. Boehm, “The effects of age on lipopolysaccharide-induced cognitive deficits and interleukin-1β expression,” Behavioural Brain Research, vol. 217, no. 2, pp. 481–485, 2011. View at Publisher · View at Google Scholar · View at Scopus
  85. N. Terrando, A. R. Fidalgo, M. Vizcaychipi et al., “The impact of IL-1 modulation on the development of lipopolysaccharide-induced cognitive dysfunction,” Critical Care, vol. 14, article R88, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. A. Mazarati, M. Maroso, V. Iori, A. Vezzani, and M. Carli, “High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and receptor for advanced glycation end products,” Experimental Neurology, vol. 232, no. 2, pp. 143–148, 2011. View at Publisher · View at Google Scholar · View at Scopus
  87. S.-C. Tang, J. D. Lathia, P. K. Selvaraj et al., “Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid β-peptide and the membrane lipid peroxidation product 4-hydroxynonenal,” Experimental Neurology, vol. 213, no. 1, pp. 114–121, 2008. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Walter, M. Letiembre, Y. Liu et al., “Role of the toll-like receptor 4 in neuroinflammation in Alzheimer’s disease,” Cellular Physiology and Biochemistry, vol. 20, no. 6, pp. 247–256, 2007. View at Publisher · View at Google Scholar
  89. S. Frank, E. Copanaki, G. J. Burbach, U. C. Müller, and T. Deller, “Differential regulation of toll-like receptor mRNAs in amyloid plaque-associated brain tissue of aged APP23 transgenic mice,” Neuroscience Letters, vol. 453, no. 1, pp. 41–44, 2009. View at Publisher · View at Google Scholar · View at Scopus
  90. M. A. Panaro, D. D. Lofrumento, C. Saponaro et al., “Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson's-like disease,” Immunopharmacology and Immunotoxicology, vol. 30, no. 4, pp. 729–740, 2008. View at Publisher · View at Google Scholar · View at Scopus
  91. M. Casula, A. M. Iyer, W. G. M. Spliet et al., “Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue,” Neuroscience, vol. 179, pp. 233–243, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. M. De Paola, A. Mariani, P. Bigini et al., “Neuroprotective effects of toll-like receptor 4 antagonism in spinal cord cultures and in a mouse model of motor neuron degeneration,” Molecular Medicine, vol. 18, no. 6, pp. 971–981, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. M. R. Minter, J. M. Taylor, and P. J. Crack, “The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease,” Journal of Neurochemistry, vol. 136, no. 3, pp. 457–474, 2016. View at Publisher · View at Google Scholar
  94. M. Song, J. Jin, J.-E. Lim et al., “TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease,” Journal of Neuroinflammation, vol. 8, pp. 92–106, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. K. G. Mawuenyega, W. Sigurdson, V. Ovod et al., “Decreased clearance of CNS β-amyloid in Alzheimer's disease,” Science, vol. 330, no. 6012, pp. 1774–1776, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. S. E. Hickman, E. K. Allison, and J. El Khoury, “Microglial dysfunction and defective β-amyloid clearance pathways in aging alzheimer's disease mice,” Journal of Neuroscience, vol. 28, no. 33, pp. 8354–8360, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. J.-P. Michaud, M. Hallé, A. Lampron et al., “Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer's disease-related pathology,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 5, pp. 1941–1946, 2013. View at Publisher · View at Google Scholar · View at Scopus
  98. C. Noelker, L. Morel, T. Lescot et al., “Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease,” Scientific Reports, vol. 3, article 1393, 2013. View at Publisher · View at Google Scholar · View at Scopus
  99. N. Stefanova, L. Fellner, M. Reindl, E. Masliah, W. Poewe, and G. K. Wenning, “Toll-like receptor 4 promotes α-synuclein clearance and survival of nigral dopaminergic neurons,” American Journal of Pathology, vol. 179, no. 2, pp. 954–963, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. L. Fellner, R. Irschick, K. Schanda et al., “Toll-like receptor 4 is required for α-synuclein dependent activation of microglia and astroglia,” Glia, vol. 61, no. 3, pp. 349–360, 2013. View at Publisher · View at Google Scholar · View at Scopus
  101. M. D. Nguyen, T. D'Aigle, G. Gowing, J.-P. Julien, and S. Rivest, “Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis,” The Journal of Neuroscience, vol. 24, no. 6, pp. 1340–1349, 2004. View at Publisher · View at Google Scholar · View at Scopus
  102. M. Maroso, S. Balosso, T. Ravizza et al., “Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures,” Nature Medicine, vol. 16, no. 4, pp. 413–419, 2010. View at Publisher · View at Google Scholar · View at Scopus